Denileukin Diftitox and Hyper-CVAD in the Treatment Human T-Cell Lymphotropic Virus 1–Associated Adult T-Cell Leukemia/Lymphoma
DiVenuti G, Nawgiri R, Foss F. Denileukin Diftitox and Hyper-CVAD in the Treatment Human T-Cell Lymphotropic Virus 1–Associated Adult T-Cell Leukemia/Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2003, 4: 176-178. PMID: 14715100, DOI: 10.3816/clm.2003.n.027.Peer-Reviewed Original ResearchConceptsAdult T-cell leukemia/lymphomaT-cell leukemia/lymphomaDenileukin diftitoxLeukemia/lymphomaClinical remissionHuman T-cell lymphotropic virus-1Human T-cell lymphotropic virusCell leukemia/lymphomaBone marrow myelofibrosisComplete clinical remissionBone marrow biopsyLymphotropic virus-1Acute T-cell leukemiaNormal hematopoiesisT-cell leukemiaLeukemic T cellsExtensive myelofibrosisHyper-CVADInitial therapyMaintenance therapyClinical improvementClinical manifestationsMarrow biopsyDisease progressionT cellsOverview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic Approaches
Foss F. Overview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic Approaches. Leukemia & Lymphoma 2003, 44: s55-s61. PMID: 15202526, DOI: 10.1080/10428190310001623757.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaNovel agentsTherapeutic approachesAcute T-cell leukemia/lymphomaAdvanced refractory cutaneous T cell lymphomasEarly-stage cutaneous T-cell lymphomaMycosis fungoides/Sézary syndromeRefractory cutaneous T-cell lymphomaPeripheral T-cell lymphomaAllogeneic stem cell therapyT-cell leukemia/lymphomaDemonstrated survival benefitYear of diagnosisAdvanced-stage patientsCytokine receptor antagonistsProbability of progressionNovel therapeutic approachesLeukemia/lymphomaNew therapeutic approachesNF-kappaB inhibitorHistone deacetylase inhibitorsStem cell therapyCytotoxic regimensExtracutaneous disease